Regeneron signs $2.32 billion deal with Parabilis for Helicon conjugates
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
The multi-target collaboration combines Regeneron’s industry-leading antibody capabilities with Parabilis’ novel Helicon peptide platform
She brings extensive expertise in managing global and domestic procurement operations
The company intends to file an IND submission by the end of this year and begin clinical studies in 2027
Despite the strong results, investigators cautioned that the study has limitations, including its open-label Phase II design, lack of randomization, and reliance on a historical external control arm
AstraZeneca highlighted the move as a major step toward earlier intervention in curable disease
According to the analysis, just 23% of patients aged 18–29 were formally diagnosed with TD
Baxfendy works in a fundamentally different way from current therapies
Nationwide preventive health initiative aims to make cardiovascular screening at age 30 a standard healthcare milestone
Subscribe To Our Newsletter & Stay Updated